SUD Residential denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sud residential are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Residential SUD Treatment — "Not FDA-Approved"

Residential substance use disorder (SUD) treatment is a level of care, not a drug or device — the FDA does not approve or disapprove it. When BCBS applies a "not FDA-approved" denial code to residential SUD services, the denial typically reflects either a coding mismatch (the claim was processed under a benefit category that triggers a drug/device review), a plan exclusion for a specific ancillary service billed within the stay, or an administrative error in routing. This type of denial is highly appealable because the regulatory framework it invokes simply does not apply to residential behavioral health care.

## Why This Denial Is Appealable

Federal parity law (the Mental Health Parity and Addiction Equity Act, MHPAEA) requires that treatment limitations applied to mental health and substance use disorder benefits be no more restrictive than those applied to analogous medical or surgical benefits. Applying an FDA-approval criterion to a level-of-care determination — something that would never be applied to an inpatient medical stay — is a textbook parity violation. Document the analogy explicitly in your appeal.

## Federal Appeal Framework

• Internal appeal (Level 1): Submit within the plan's stated deadline (typically 180 days from the denial notice). Request the specific denial rationale in writing and the clinical criteria used.
• External review (ACA §2719): If the internal appeal is denied, you have the right to independent external review. The ~4-month window to request external review typically begins from the date of the final internal denial. An accredited Independent Review Organization (IRO) will evaluate the denial on the clinical and regulatory merits.
• ERISA §503 (self-funded plans): If your plan is employer-sponsored and self-funded, you retain the right to a full-and-fair review, including access to the specific plan language and clinical criteria driving the denial.
• Expedited review: If the patient is currently in treatment or faces imminent discharge, request expedited internal and external review simultaneously — decisions are required within 72 hours.
• State insurance commissioner: File a parallel complaint citing the MHPAEA parity argument.

## Documentation to Gather

• Diagnosis confirmation from the treating clinician (SUD diagnosis with severity documentation)
• ASAM Level of Care assessment or equivalent clinical assessment justifying the residential level
• Prior treatment history: outpatient and intensive outpatient attempts, dates, outcomes, reasons for step-up
• Medical records documenting clinical severity and risk factors requiring 24-hour supervision
• Prescriber/treating physician letter of medical necessity
• The insurer's own published behavioral health coverage policy and any clinical criteria guidelines cited in the denial

## Criteria-Mapping Structure

Pull the exact language from (a) BCBS's published behavioral health medical policy and (b) any ASAM or equivalent criteria the plan references. For each stated requirement, pair it with a specific chart entry, assessment score, or clinician statement that satisfies it. Present this as a side-by-side table in your appeal letter. Conclude by noting that no FDA-approval requirement exists for this level of care and that imposing one violates MHPAEA.